TransMedics Group (TMDX) Misses Q2 EPS by 6c, Revenues Beat; Raises FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
TransMedics Reports Second Quarter 2022 Financial Results
August 1, 2022 4:06 PM EDTAccelerated Commercial Momentum to Achieve Net Revenue of $20.5 million
2022 Revenue Guidance Range Raised to $67 million to $75 million
ANDOVER, Mass., Aug. 1, 2022 /PRNewswire/ --Â TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2022. The Company also announced it entered into a new $60 million five-year loan agreement with CIBC Innovation Banking ("CIBC"), which was fully funded upon closing.
... More